Author

E. Arutyunova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Biophysics· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:protein folding & dynamics· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

M. J. Lemieux· 5 shared H. S. Young· 4 shared D. L. Tyrrell· 3 shared J. C. Vederas· 3 shared M. B. Khan· 3 shared T. Lamer· 3 shared C. Fischer· 2 shared J. Lu· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

M. J. Lemieux

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals

S. A. Chen, E. Arutyunova, J. Lu, M. B. Khan, W. Rut, M. Zmudzinski, S. Shahbaz, J. Iyyathurai, E. Moussa, Z. Turner, B. Bai, T. Lamer, J. A. Nieman, J. C. Vederas, O. Julien, , M. J. Lemieux

The paper examines how SARS-CoV-2 Mpro variants affect viral and host protein processing but maintain antiviral potency.

bioRxiv · Jan 28, 2023 · PreprintBiochemistry

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1

J. L. M. Law, M. Logan, M. Joyce, A. Landi, D. Hockman, K. Crawford, J. Johnson, G. LaChance, H. Saffran, J. Shields, E. Hobart, R. Brassard, E. Arutyunova, K. Pabbaraju, M. Croxen, , M. Houghton

This study shows that recombinant SARS-CoV-2 RBD induces neutralizing antibodies against variant strains and SARS-CoV-1, suggesting its potential as a vaccine candidate or booster.

bioRxiv · May 10, 2021Microbiology

N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro

E. Arutyunova, M. B. Khan, C. Fischer, J. Lu, T. Lamer, W. Vuong, M. J. van Belkum, R. T. McKay, D. L. Tyrrell, J. C. Vederas, H. S. Young, M. J. Lemieux

This study characterizes the reversible inhibition of SARS-CoV-2 and SARS-CoV Mpro by GC376, showing nanomolar Ki values and domain swapping in the drug-bound structures.

bioRxiv · Feb 16, 2021Biophysics

Insights into the catalytic properties of the mitochondrial rhomboid protease PARL

L. Lysyk, R. Brassard, E. Arutyunova, V. Siebert, Z. Jiang, E. Takyi, M. Morrison, H. S. Young, M. K. Lemberg, A. J. O'Donoghue, M. J. Lemieux

This study investigates the catalytic properties of the mitochondrial rhomboid protease PARL using in vitro assays, revealing substrate preferences and activity enhancements under specific conditions.

bioRxiv · Jul 27, 2020Biochemistry

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

W. Vuong, M. B. Khan, C. Fischer, E. Arutyunova, T. Lamer, J. Shields, H. A. Saffran, R. T. McKay, M. J. van Belkum, M. Joyce, H. S. Young, D. L. Tyrrell, J. C. Vederas, M. J. Lemieux

This paper shows that feline coronavirus drugs inhibit SARS-CoV-2 main protease and block virus replication in cell culture with low toxicity.

bioRxiv · May 3, 2020Biochemistry